Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Authors:
Mohan M; Monge J; Shah N; Luan D; Forsberg M and 16 more

Journal:
Blood Cancer J

Publication Year: 2024

DOI:
10.1038/s41408-024-01003-z

PMCID:
PMC10914756

PMID:
38443345

View on PubMed View on PMC View Publisher
Journal Information

Journal Title: Blood Cancer J

Detailed journal information not available.

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests The authors declare no competing interests."

Evidence found in paper:

"We thank our patients and families for the opportunity to be involved in their care and all the contribution to the advancement in the field. Acknowledgement of research support for the study: Advancing a Healthier Wisconsin Endowment-CTSI KL2 award (M.M). List of where and when the study has been presented in part elsewhere, if applicable: This work will be partly presented as an oral abstract at the 65th American Society of Hematology Annual Meeting and Exposition, Dec 9-12, 2023, San Diego, California."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025